Sign up to our newsletter Subscribe
Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?
Real-World Evidence (RWE)
RWE describes evidence relating to patient health or experience or care delivery collected in the ‘real world’, i.e. outside of controlled research studies. The quality of RWE varies widely and its use is not consistently accepted but it has the potential to reduce uncertainty and improve decision-making.
Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations
Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions
